Tue.Apr 16, 2024

article thumbnail

Another Caplyta trial win moves Intra-Cellular closer to FDA filing in major depressive disorder

Fierce Pharma

Intra-Cellular Therapies has unveiled another positive late-stage trial readout for Caplyta, taking another step toward a potential blockbuster label expansion for the depression drug. | Intra-Cellular Therapies has unveiled another positive late-stage trial readout for Caplyta, taking another step toward a potential blockbuster label expansion for the depression drug.

FDA 308
article thumbnail

Smart sensor cleared for use with AZ asthma, COPD inhalers

pharmaphorum

A smart sensor developed by Adherium has been cleared by the FDA for use with AstraZeneca's asthma inhaler Airsupra and Breztri for COPD.

FDA 131
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With Vyvgart 'firing' in myasthenia gravis, argenx lays launch plans for next potential autoimmune approval: CEO

Fierce Pharma

Despite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, could tackle a wide array of autoimmune diseases linked to immuno | Argenx is bolstering its case for Vyvgart’s CIDP potential and preparing for a possible launch later this year—all while the company continues to prove the medication’s worth in its inaugural generalized myasthenia gravis indication.

284
284
article thumbnail

India sees insignificant revision to price ceiling in 2024

Pharmaceutical Technology

The price ceiling policy has been in place for more than 20 years, but it has neither been very successful nor free of consequences for pharma companies.

Pharma 111
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

J&J reports strong sales numbers for Tecvayli, bolstering company's multiple myeloma 'stronghold'

Fierce Pharma

For the first time, Johnson & Johnson has reported sales numbers for its novel multiple myeloma treatment Tecvayli and they indicate that the bispecific, which was approved in October 2022, is | For the first time, Johnson & Johnson is reporting sales of its multiple myeloma drug Tecvayli, which is off to a strong launch and contributing to the company's overall strength in treating the disease.

Sales 264
article thumbnail

Two Chairs Rakes In $72M For Its Hybrid Therapy Platform

MedCity News

Two Chairs, a startup offering hybrid behavioral health care, closed a $72 million Series C funding round. The company’s focus on measuring outcomes and dedication to care quality assurance are two key factors that differentiate it from other mental health startups, CEO Alex Katz said. The post Two Chairs Rakes In $72M For Its Hybrid Therapy Platform appeared first on MedCity News.

108
108

More Trending

article thumbnail

Guidance and Education For Employees Facing a Cancer Journey

MedCity News

In vulnerable moments when employees need it most, virtual specialty care delivers a human connection that offers empathy, support, and guidance. The post Guidance and Education For Employees Facing a Cancer Journey appeared first on MedCity News.

Education 108
article thumbnail

Biogen CEO Viehbacher sees 2023 pay fall to $4M after massive welcome package

Fierce Pharma

After getting a fat check worth $30.5 million for joining Biogen as the CEO in late 2022, Chris Viehbacher saw his 2023 pay drop to $4.1 million as the Big Biotech continues to struggle. | After getting a fat check worth $30.5 million for joining Biogen as the CEO in late 2022, Chris Viehbacher saw his 2023 pay drop to just $4.1 million as the Big Biotech continues struggling.

144
144
article thumbnail

Depression Trial Win Moves Intra-Cellular Drug Closer to Label Expansion & Blockbuster Status

MedCity News

Intra-Cellular Therapies reported its drug Caplyta met the main and secondary goals in the first of three pivotal studies in major depressive disorder. Success in two of them could support expanding the label of the drug, which is currently approved in schizophrenia and bipolar depression. The post Depression Trial Win Moves Intra-Cellular Drug Closer to Label Expansion & Blockbuster Status appeared first on MedCity News.

Biopharma 108
article thumbnail

At Princeton University Press, The Mission is “Our Compass”

Copyright Clearance Center

In a publishing environment buffeted by digital disruption and calls for open access, university presses in 2024 must manage to remain relevant and sustainable even as their audiences grow.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Boehringer says R&D pipeline is the best in its long history

pharmaphorum

Boehringer Ingelheim says the strongest R&D pipeline in its history is set to deliver 25 new product launches between now and 2030

116
116
article thumbnail

Novartis releases new data for innovative rare kidney disease treatment

European Pharmaceutical Review

Novartis has released new data from the first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with the rare kidney disease IgA nephropathy (IgAN). Pre-specified interim analysis results from the Phase III APPLAUSE-IgAN clinical trial were presented at the 2024 World Congress of Nephrology (WCN).

article thumbnail

‘Stiffness’ of cells could give early warning of cancer

pharmaphorum

Researchers from the UK have developed an endoscopic device that uses 3D imaging to look at the stiffness of cells and could diagnose cancer earlier.

110
110
article thumbnail

Teva enters into oncology biosimilar licensing agreement

European Pharmaceutical Review

A new global licensing agreement is set to advance development of an oncology biosimilar candidate. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Spain-based biopharmaceutical company mAbxience, have entered into a strategic deal for a drug candidate that is in development for treating multiple indications in the oncology space.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AHIP, AMA, NAACOS Release Playbook for Value-Based Care

MedCity News

AHIP, the AMA and NAACOS released a playbook last week that provides the best practices for value-based care. It is based on experiences from physicians, value-based care entities and payers. The post AHIP, AMA, NAACOS Release Playbook for Value-Based Care appeared first on MedCity News.

article thumbnail

GSK trails after Pfizer in 5-in-1 meningococcal vaccine race

pharmaphorum

FDA starts review of GSK’s 5-in-1 meningitis vaccine, cueing up a decision early next year, as it tries to chase down Pfizer's recently-approved Penbraya

FDA 105
article thumbnail

European and Japanese Pharmacopoeias partner to harmonise pharmacopoeial standards

European Pharmaceutical Review

A new bilateral prospective harmonisation project between the European Pharmacopoeia (Ph. Eur.) and the Japanese Pharmacopoeia (JP) will focus on pharmacopoeial standards for active substance and medicinal product monographs. Through the harmonisation, alignment of the pharmacopoeial standards in different regulatory jurisdictions, is aimed at decreasing the burden on drug manufacturers to do different compendial tests, according to the organisation European Directorate for the Quality of Medici

article thumbnail

Norgine seeks approval for high-risk neuroblastoma treatment

Pharmaceutical Technology

Norgine has sought approval for eflornithine (DFMO) for the treatment of patients with high-risk neuroblastoma (HRNB).

Patients 111
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

EConsent Workflows Must Evolve to Support Interoperability and Health Equity

MedCity News

Former U.S. CTO Aneesh Chopra will moderate a webinar on April 16 at 1pm ET on eConsent, The post EConsent Workflows Must Evolve to Support Interoperability and Health Equity appeared first on MedCity News.

article thumbnail

Intra-Cellular sets up $500m offer on Caplyta depression win

pharmaphorum

Shares in Intra-Cellular Therapies rose after it reported Caplyta was effective for major depressive disorder (MDD), in a phase 3 trial.

98
article thumbnail

Bio-Rad and Oncocyte partner to develop and commercialise transplant monitoring products

PharmaTimes

Solid organ transplantation is used to treat end-stage organ failure, including the kidneys

108
108
article thumbnail

Bill Whitford of Arcadis Discusses 3D Printing for Biologics (INTERPHEX 2024)

PharmaTech

At INTERPHEX, Bill Whitford, Strategic Solutions leader at Arcadis, discusses the progress made in 3D bioprinting toward commercial biologics production.

69
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

UCL study reveals carbon beads could help reduce progression of liver disease

PharmaTimes

Liver cirrhosis, caused by long-term liver damage, is estimated to affect around 100 million people worldwide

97
article thumbnail

Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?

PharmaVoice

New clinical trial starts are picking back up, but are still far below their bustling pre-war level.

81
article thumbnail

Pharma Pulse 4/16/24: Diabetes Weight Loss Drugs Could Reduce Risk of MS, Walmart Health Expands in Texas & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 103
article thumbnail

Risk adjusted net present value: What is the current valuation of Novartis’s XXB-750?

Pharmaceutical Technology

XXB-750 is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Systolic Heart Failure.

Leads 75
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

6 Best Industrial Sales Training Resources

Spotio

If you want your team to succeed in the industrial sales sector your reps need to become more than order-takers. They need to take a proactive approach to find quality buyers for themselves. This is much easier said than done, of course. Thankfully, there are plenty of effective industrial sales training programs available. Each one will teach your reps to close more deals—often in less time and with less effort than before.

article thumbnail

The IRA Impact: Navigating Its Evolving Complexities

PharmExec

Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.

Pharma 52
article thumbnail

Clarify announces Negotiation Opportunity tool to enhance price transparency solution

Clarify Health

Although price transparency files are available, the volume and complexity of available data makes it difficult for healthcare organizations to clearly understand their competitive rate position—where their negotiated rates may be significantly above or below market rates. Finding insights in price transparency data can be like finding a needle in a haystack.

article thumbnail

An Ethical Outlook for Obesity Drugs

PharmExec

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses what to expect from the obesity space in the next five years.

Ethics 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A